C4 Therapeutics

CCCC Micro Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$2.82

+4.44% today

52W: $1.08 – $3.82

52W Low: $1.08 Position: 63.4% 52W High: $3.82

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

7.65x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$275.2M

Market Capitalization

Revenue Growth

112.8%

YoY Revenue Growth

Profit Margin

-292.08%

Net profit margin

ROE

-44.44%

Return on Equity

Beta

2.86

Market sensitivity

Short Interest

14.66%

% of float sold short

Avg. Volume

2,120,514

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

7 analysts

Avg. Price Target

$11.57

+310.33% upside

Target Range

$6.00 – $30.00

About the Company

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGA

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 104 Exchange: NMS